New this year, the Neuropathic Pain Therapeutics digital summit is the only meeting for large pharma, biotech and pioneering academics addressing the industry’s key challenges of understanding the underlying pathophysiology of neuropathic pain, identifying novel therapeutic targets for neuropathic pain and more!

With an ageing global population and unabating opioid crisis, the clinical need for novel neuropathic pain therapeutics has reached a critical level. This meeting will be the center point for exploring novel drug modalities for neuropathic pain including: NaV1.7 channel inhibitors, antisense oligonucleotides, matrix metalloproteinase inhibitors, gene therapy, anti-TRPV1 antibody, cannabinoid-derived pharmaceutical, neuroimmune-targeted, medical device approaches and more.

From harnessing preclinical models for pain drug discovery to identifying pain biomarkers and novel non-addictive neuropathic pain drug modalities in development, this conference will delve into challenges that have obstructed the clinical success of neuropathic pain therapeutics.

Learn from 20+ thought leaders in our expert speaker faculty, access 18+ hours of content exploring the latest advances in the neuropathic pain therapy field and form meaningful connections during the multiple and varied hybrid networking sessions built into the event.

Join this industry-dedicated virtual forum as we unite drug developers and academics to tackle the most critical drug development challenges in accelerating novel neuropathic pain therapeutics into the clinic and to patients in need.

To know more about Neuropathic Pain Therapeutics Summit please click here.